key: cord-0812914-kv1zyy58
authors: Ou, Lailiang; Li, Wenzhong; Liu, Yi; Zhang, Yue; Jie, Shen; Kong, Deling; Steinhoff, Gustav; Ma, Nan
title: Animal Models of Cardiac Disease and Stem Cell Therapy
date: 2010-11-26
journal: Open Cardiovasc Med J
DOI: 10.2174/1874192401004010231
sha: ccb533d872f914aee01fd533f330c6d768da14c5
doc_id: 812914
cord_uid: kv1zyy58

Animal models that mimic cardiovascular diseases are indispensable tools for understanding the mechanisms underlying the diseases at the cellular and molecular level. This review focuses on various methods in preclinical research to create small animal models of cardiac diseases, such as myocardial infarction, dilated cardiomyopathy, heart failure, myocarditis and cardiac hypertrophy, and the related stem cell treatment for these diseases.

Cardiovascular disease is considered the major cause of morbidity and mortality throughout the world. Over the past several years, great achievement has been made in the treatment/management of cardiovascular diseases, which have depended on the use of experimental animal models. With the use of disease models in preclinical research, a large amount of information has been generated, which has outlined the pathogenesis, progression and mechanisms underlying cardiovascular diseases at the cellular and molecular level. This has allowed the development of many effective treatment strategies. Cardiovascular disease models have been developed in many species, including large animals such as swines and dogs [1, 2] , as well as, small animals such as rats and mice [3] [4] [5] . Small animal models are more applicable to research work compared to large animal models due to their inexpensiveness, convenience in handling and the vast amount of scientific literature available [6] . In this review, we mainly focus on various methods used by investigators to create small animal models of cardiac disease, such as myocardial infarction (MI), dilated cardiomyopathy (DCM), heart failure (HF), myocarditis and cardiac hypertrophy (CH) and the related stem cell treatment for these diseases.

MI is one of the leading causes of death in the world, induced by a blockage in coronary arteries as a result of atherosclerosis or thrombosis [7] . It is characterized by necrosis of myocardiocytes due to a reduction in blood supply. The conventional clinical treatments, such as percutaneous coronary intervention, coronary-artery bypass graft surgery and anti-or dissolution-thrombotic therapy can reduce death rate to a certain extent [8] . Heart transplantation is greatly restricted due to the limited source of donor hearts. Therefore, more effective approaches are urgently needed to treat this disease.

On the basis of animal models established in experimental research, the mechanisms underlying the development of cardiovascular diseases at the cellular and molecular level have been clarified and the potential treatment options using protein, gene and stem cell therapy have been proposed, which have achieved satisfactory results [9] [10] [11] [12] [13] [14] [15] [16] [17] .

MI in animal models can be mainly achieved by two methods. The first is to fully block or partially narrow the coronary artery, which often leads to acute ischemia. This can be achieved by a surgical procedure or by drug intervention. The other method is to induce atherosclerosis in coronary arteries, which would more closely mimic the disease progression in humans; however, this approach is rarely adopted in research studies, since it is time-consuming [18] .

In this section we focus on the commonly used methods to create MI in small animals.

Occluding different regions of the coronary arteries via a thoracotomy to induce MI has been used for decades [19] . Ligation of the left anterior descending coronary artery (LAD) to create anterior wall infarction of the left ventricle (LV) has been described by many workers [19] [20] [21] [22] [23] . The surgical procedure can be divided into three steps. In brief, the heart of an animal under anaesthesia is exposed following a left thoracotomy at the fourth intercostal space. The pericardium is carefully broken and the LAD ligated with a suture placed just distally (1mm) from tip of the left auricle. The procedure is considered successful if the electrocardiogram (ECG) shows ST-segment elevation and the anterior wall of the left ventricle becomes whitish. Finally, the lungs are inflated and the chest closed.

This permanent ligation of the LAD can cause irreversible damage to the myocardium, which is stable and easily reproduced. It has been extensively employed in studies on MI therapy using techniques such as; cell implantation, genetic modification and the administration of cytokines [24] [25] [26] [27] [28] . Further ligation of the LAD can also produce a HF model or an ischemia-reperfusion model by subsequently removing the occlusion [29, 30] . However, the difficulty in operating on small rodents, particularly mice and the relatively high surgical mortality, due to the size of the wound created has to be addressed. In addition, the coronary ligation procedure often gives rise to apical aneurysmatic infarcts of variable size.

The surgical procedures for cauterization or cryo-injuryinduced MI have been previously studied using various animal models. In brief, the heart is exposed following intercostal thoracotomy. Cauterization or cryo-injury is induced with an electrocoagulation knife for 1 to 2 seconds or a cryoprobe for 10s, respectively, on the anterior LV free wall [31, 32] . The position of the probe can be set accurately using the pulmonary artery as an anatomical landmark.

The MI caused by cauterization or cryo-injury is stable and easily produced in a short period of time, without the interference of the coronary arteries collateral circulation [31] . It is particularly suitable for use in small animal such as the mouse. The necrosis of myocardiocytes is ascribed to tissue damage caused by burning or the ultra-low temperature. Unfortunately, cauterization or cryo-injury is not guaranteed to induce myocardium ischemia [33] or tissue damage that closely mimics the natural ischemia-initiated infarction. In fact, myocardial injury from cauterization or cryo-injury shows pathophysiological changes that are not associated with myocardial infarction [33] .

The balloon occlusion model was developed from percutanous translaminal coronary angioplasty and was applied in large animal models [6, 34] . Cohen et al. developed this occlusion model in small animals by encircling a superficial branch of the rabbit left coronary artery with a balloon occluder [6] . Briefly, after left thoracotomy, the open end of a balloon occluder is placed around the branch of the exposed left coronary artery (LCA). The occluder is connected to a vacuum pump or compressed air to control balloon inflation and coronary occlusion. The use of this model reduces mortality and the size of the surgical wound when compared with LAD ligation-induced MI. The procedure is reliable and reproducible, allowing the accurate positioning of the balloon, making it the first choice model to induce post-infarct reperfusion. However, balloon angioplasty requires a high level of surgical expertise and is not easily applicable in small animals without extensive training [35] [36] [37] [38] .

Drug-induced myocardial ischemia is a convenient procedure, since it does not require complicated surgery. Isoproterenol, adriamycin and ergonovine have been often used to induce MI. Signal et al. induced myocardial ischemia in rats with isoproterenol (a synthetic -adrenergic agonist) [39] . Similarly, Chagoya et al. developed a rat MI model by utilising isoproterenol [40] ; and Arteaga de Murphy and his group successfully duplicated the MI model in rats with a subcutaneous injection of isoproterenol [41] . While, Arnolde et al. created an ischemia model in rabbits by the intraperitoneal injection of adriamycin [42] .

Drug-induced ischemia can be easily achieved, since it increases myocardial oxygen consumption or induces coronary artery spasm to reduce blood flow; however, drug safety and the difficulty in accurately positioning the infarct region make this model rarely used in clinical research.

Studies using myocardial infarct animal models have indicated that transplantation of mesenchymal stem cells (MSC) [23, [43] [44] [45] , umbilical cord blood cells [46, 47] , bone-marrow-derived haematopoietic stem cells [32, 48] , skeletal myoblasts [49] , endothelial progenitor cell (EPC) [50] , cardiac stem cells [51, 52] , embryonic stem cells (ESC) [25] , or induced-pluripotent stem cell [53] have the potential to improve the function of ventricular muscle after MI. Clinical trials have also produced some encouraging results. However, the current experimental evidence suggests that the benefits of cell therapy are modest. Several recent reviews have summarized systematically the application of stem cell following MI [54, 55] . The past decade has shown that translating the potential benefit of stem cell therapy into actual clinical practice still needs a lot of work and many barriers would need to be overcome before this therapy can attain its full potential.

DCM is a primary myocardial disease characterized by chamber dilation associated with impaired systolic and diastolic function [56, 57] . It starts from asymptomatic LV dilatation or impaired systolic function, exercise-induced symptoms, and finally to overt congestive heart failure (CHF). The onset of DCM can be linked to viral infection, genetic abnormalities, and autoimmune mechanisms [58] . A number of animal models of DCM have been developed to elucidate the mechanism responsible for the pathophysiological features of DCM and to establish potential treatment strategies.

This section of the review focuses on viral infection, genetic abnormalities, and autoimmune animal model and the application of stem cells to treat DCM.

Increasing evidence shows that a large proportion of DCM cases are mediated by autoimmune processes [59, 60] . Various antimyocardial antibodies circulating in the serum are associated with myocyte injury, which is detected in 85% of DCM patients [61] . Furthermore, familial occurrence of DCM with the presence of autoantibodies and abnormal cytokine profiles in relatives with asymptomatic LV enlargement can account for 20-30% of cases [62, 63] , suggesting the involvement of abnormal humoral and cellular immunity in the early development of the disease.

1-ECII the anti-1-adrenergic receptor antibody against the second extracellular receptor loop represents a potent "self-antigen" that induces DCM [64, 65] . Matsui et al. using a rabbit model were the first to presented data on the development of biventricular dilatation. They found an upregulation of total cardiac -AR ( -adrenergic receptor) following immunization with 1-ECII-homologous peptide [66] . Intraperitoneal injection of blood lymphocytes either from immunized anti-1-ECII-positive rabbits [67] , or from anti-1-AR-positive DCM patients [68] into immunodeficient mice can avoid the expected immune reaction against rabbit or human non-self proteins, which can lead to the early stage of cardiac dilatation. Treatment of mice with certain human leukocyte antigen alleles can also induce autoimmune myocarditis followed by the subsequent development of DCM [69] . Daniel et al. induced DCM in a mouse model with the application of KXXS-motif [70] . The autoimmune DCM model can also be created by viral infection, immunization with heart-specific autoantigens, or from genetically predisposed strains.

Viral myocarditis is a common cause of acquired DCM in humans. The pathogenesis of viral myocarditis and the pathophysiological features of DCM depend on the viral strain and the genetic background [71] .

Transduction of Coxsackie virus genomic constructs with a cardiac-specific promoter in transgenic mice induced DCM with features consistent with human cardiomyopathy [72] . Recent evidence showed that Coxsackie virus myocarditis can lead to DCM [73] . Acute coronavirus infection can also results in virus-induced myocarditis and CHF. After infection, nearly half of the rabbits showed an increased heart weight and heart weight-to-body weight ratios, biventricular dilation, myocyte hypertrophy, myocardial fibrosis, and myocarditis similar to the development of DCM [74] . LP-BM5 murine AIDS (MAIDS) retrovirus induced DCM in the absence of chronic cardiac inflammation, suggesting MAIDS retroviral infection can lead to DCM without myocarditis [75] .

Approximately 20% of DCM patients have a gene mutation [62] , which affects the myosin heavy chain [76] , cardiac actin [77] , tropomyosin [78] , or troponin [79] , inducing a functional impairment of the referred proteins. Recent investigations have focused on the genetic mechanisms and stress pathways [76] , cytoskeletal abnormalities [77] and signaling pathways for CH and HF in DCM [77] . Yasuhiro et al. focused on the mouse models of DCM, together with commentary on the naturally occurring DCM in the hamster [80] based on the subcellular localization and the potential functional importance of the gene products involved.

A number of experimental studies and clinical trials support cellular cardiomyoplasty as a promising therapeutic strategy to improve cardiac function after acute MI [81, 82] , however, much less information is available on the therapeutic potential of MSCs for DCM. Noritoshi et al. investigated the effect of MSCs on DCM in animals following immunization [83] . The results showed that MSC transplantation increased capillary density and decreased the collagen volume fraction in the myocardium, resulting in decreased LV enddiastolic pressure. Bone marrow-derived mononuclear cell therapy in DCM limited cellular apoptosis, inflammatory and oxidative responses, up-regulated the expressions of Cx43, PKC, and energy transcription factors and improved LV function [84] . In addition, intracoronary administration of bone marrow-derived progenitor cells improved coronary microvascular function in DCM [85] . Hence, stem cell transplantation has great potential as a new therapeutic strategy for the treatment of DCM.

HF is associated with 50% survival at 5 years. The use of animal models is indispensable in understanding the pathophysiology of HF and to evaluate the efficacy and efficiency of novel therapeutic approaches such as gene therapy, the use of mechanical devices and new surgical procedures. This section presents the most common in vivo models used to study HF.

These methods allow complete or partial occlusion of coronary artery branches in animal models. Hence, they are applicable to induce HF [86, 87] , and coronary stenosis for the investigation of hibernating myocardium. Briefly, a left anterolateral thoracotomy is performed followed by an incision of the pericardium; a branch of the LCA is exposed and the hydraulic occluder placed around the vessel. The occluder is then inflated to induce partial stenosis or complete occlusion. An ultrasonic flow probe can be placed distally to the occluder to control the degree of occlusion and record the downstream flow through the LCA [88] . An ameroid constrictor can also be implanted in a similar way. At body temperature, the casein plastic ring around the vessel will gradually narrow, due to the hygroscopic property of the material. The complexity of placing the hydraulic occluder and ameroid constrictor mean that these procedures are not appropriate for use in small animal models for investigating MI-induced HF [86, 87] .

Pfeffer et al. created HF in rats by coronary artery ligation [89] . Rats with an infarction size greater than 46% developed CHF after 21 days, with symptoms of elevated filling pressures, reduced cardiac output, and a minimal capacity to respond to pre-and after-load stress. The impairment of LV function was closely associated with the extent of myocardial loss [89] . Animal mortality from HF seems to be strain-dependent, since Sprague-Dawley and Lewis rats have a mortality rate of 36% and 16%, respectively [90] .

Coronary artery embolisation-induced HF is based on intracoronary embolisation with microspheres [91] , agarose or polystyrene beads or the intracoronary injection of thrombin and autogenous blood with fibrinogen [92] . Sabbah et al. used dogs that underwent 3 to 9 catheter-mediated intracoronary embolisation 1-3 weeks apart [90] . The embolisation was discontinued when the ejection fraction of the LV was less than 35%. In this model coronary artery embolisation increased the LV end-diastolic pressure, which was accompanied by a significant rise in pulmonary artery wedge pressure and systemic vascular resistance. Three months after the embolisation, patchy myocardial fibrosis and LV hypertrophy were observed in the heart. There was also an increase in plasma levels of atrial natriuretic peptide and norepinephrine, as well as, a reduction in the number of -AR and Ltype calcium channels and the activity and protein levels of SR Ca2+-ATPase [93] .

This model can mimic the clinical situation, of patients with HF and acute coronary syndrome, since embolisationinduced atherosclerotic and thrombotic debris are deposited into the coronary microcirculation. However, one disadvantage of the model is the difficulty in accurately controlling the location or the length of coronary artery occlusion.

Incomplete narrowing of coronary arteries similar to that observed in the coronary artery occlusion animal model has been established to mimic chronic HF. In brief, a thoracotomy is performed on the chosen animal model; a probe or copper wire is inserted into the epicardium along the LCA. The LCA is ligated with the probe inside 1-2 mm from its origin. The probe is then removed, resulting in an average reduction in the luminal diameter by 42% [94] . The ST segment of the ECG should be transiently elevated during coronary occlusion if the operation is successful. An excessive coronary artery occlusion may induce persisting ST segment elevation even after removal of the probe. HF may occur as a result of chronic cardiac ischemia [95] . The coronary ligation procedure may inevitably include the ligature of some muscle mass, which could induce vessel stenosis. The maximal resting coronary blood flow can decrease by 43% 5-7 days following the operation [96] . Reparative fibrosis, myocytolytic necrosis, as well as, myocyte hypertrophy can also occur [97] .

This model lacks predictability and reliability and the degree and progression of the stenosis cannot be adjusted. After several weeks a complete occlusion of the coronary artery can develop [98] . Interestingly, the gradually increas-ing stenosis may prompt the formation of collateral vessels, similar to the situation observed in some patients.

Current therapies aim largely to attenuate the pathological remodelling that occurs after injury and to reduce risk factors for HF. Studies in animal models indicate that transplantation of bone-marrow derived stem cells, MSC, EPC or autologous umbilical cord blood mononuclear cells [99] have the potential to improve the function of ventricular muscle after HF. A number of studies showed improvement in cardiac function when bone marrow-derived stem cells were directly implanted. However, limited or no differentiation of bone marrow cells to cardiovascular cell types [100, 101] suggested that the beneficial effect was independent of tissue regeneration [102] . Some groups have shown that EPC has great promise as a potential therapeutic agent [103, 104] . However, further research is required to enhance the therapeutic efficiency of EPCs in HF.

Myocarditis can be defined as inflammation of heart muscle. It resembles a heart attack without the blockage of coronary artery. Myocarditis is often induced by a viral infection such as parvovirus B19 or less commonly non-viral pathogens such as borrelia burgdorferi (Lyme disease) or trypanosoma cruzi, or as a hypersensitivity response to drugs [105] . Myocarditis is, therefore, an infection of the heart, with inflammatory infiltrate, causing damage to the heart muscle [106] , which may or may not result in the death of heart tissue.

EAM can be induced in susceptible mice by immunization with murine cardiac myosin or cardiac myosin peptides [107, 108] , or by adoptive transfer of myosin-stimulated T cells [109] . Myosin-induced EAM is a model of inflammatory heart disease initiated by CD4+ T cells [109] . The immune-mediated cardiac damage could play a role in the pathogenesis of a subset of post-infectious human cardiomyopathies [110] . It is also possible to induce myocarditis in Lewis rats by immunization with cardiac myosin [111] or by adoptive transfer of T cells stimulated by specific peptides from cardiac myosin [112] .

The procedure to produce the animal model of EAM by active immunization with cardiac myocin has previously been described [107] . The immunogen is injected subcutaneously into mouse; 7 days later a second dose of immunogen emulsified in Complete Freund's adjuvant (CFA) is administered; 21 days after the first immunization the mouse is euthanized. The heart is immediately removed, fixed in formalin for 24 hours, stained and a histopathological assessment performed to ascertain whether EAM is established. A rapid determination of the induction of EAM can be also made by analyzing specific serum markers for cardiac injury.

Cardiac troponin I (cTnI) and cardiac troponin T (cTnT), are two proteins associated with the myocyte contractile apparatus, which will be released into the serum when myocytes are injured and can serve as markers of myocyte injury. cTnI is highly sensitive and specific for myocarditis in mice 17 -21 days after immunization. The sensitivity of cTnT measurement is maximal at day 16. Both cTnI and cTnT measurements are superior to the measurement of CK-MB for the detection of murine EAM.

The protocol for EAM induction with adoptive transfer of cardiac myosin-stimulated T cells has been reported [113, 114] . In breif, the donor mice (6 to 8 weeks old) is immunized with cardiac myosin emulsified in CFA, the spleens are harvest from these mice 12-14 days after the first immunization. The spleens are incubated in sterile tissue culture flasks for 72 hours at 37°C. Lymphocytes are separated from the red blood cells and dead cells by Ficoll-Hypaque gradient centrifugation. The T cells are enriched and the B cells removed by cytotoxic elimination using an anti-MHC class II antibody and complement. T cells are injected intravenously into the tail veins of recipient SCID mice; 21 days after the first immunization the mouse is euthanized. The heart is immediately removed, fixed in formalin for 24 hours, stained and a histopathological assessment performed to ascertain whether EAM is established.

This model is ideal for studying the role of specific cellular effectors on the induction and pathogenesis of EAM, but it is only applicable to SCID mice, which have no functional B and T cells.

The protocol to induce EAM by active immunization with bordetella is known [111] . In brief, an emulsion of the selected immunogen (cardiac myosin or cardiac myosin peptide) is prepared. On day 0 and 7, an appropriate volume of immunogen is subcutaneously injected into female Lewis rats. A solution of B. pertussis is prepared in PBS and injected into the rats intravenously on day 1 and 3; 21 days after the first immunization the rat is euthanized. The heart is immediately removed, fixed in formalin for 24 hours, stained and a histopathological assessment performed to ascertain whether EAM is established.

The injection of cardiac myosin and B. pertussis is the only way to induce EAM in rats, allowing the comparative study of the mechanism underlying disease development.

Humans infected with common viruses such as; adenovirus, enterovirus, Epstein-Barr virus, human herpes virus 6, parvovirus B19 and cytomegalovirus may have activated Tcells and associated cytokine mechanisms, [115] resulting in autoimmune myocarditis [116] . Viruses induce the initial myocardial injury, and can cause continuous low grade inflammation and enduring myocardial damage and reparative fibrosis. Inflammatory cells also produce matrix-degrading proteases [117, 118] , leading to LV dilatation and cardiac dysfunction [119] . Similar to autoimmune myocarditis, direct virus injection can cause myocarditis in three phases. The initial phase frequently passes without symptoms, since the initial damage is often prevented by the innate immune response [120] . The second phase results from immune dysregulation, triggered by the initial cardiomyocyte injury. The initial cellular and humoral immune responses may improve the outcome during phase 1; conversely, they are responsible for the harmful effect during phase 2. This is in part due to molecular mimicry [121] , which is caused by mimicked epitopes shared between the viral and cardiac antigens [122] . Finally, in the third phase, a typical DCM develops as a result of extensive myocardial injury.

It is, however, difficult to determine the virus dose/ concentration required to induce myocarditis and detect the inflammation of the myocardium during the first phase, limiting its application in preclinical research.

Stem cells play a critical role in the pathogenesis and outcome of myocarditis. Recent studies have described the role of different stem cell types and subtypes and their products in mediating cardiac dysfunction in myocarditis. Kania G et al. in vitro culture-expanded a specific population of bone marrow-derived prominin-1-expressing progenitor cells from healthy heart tissue and injected these cells intravenously into autoimmune-myocarditis animal model [123] . MSCs also have angiogenic, myogenic, and paracrine actions in the treatment of EAM. Okada H et al. determined whether MSC transplantation attenuated EAM [124] . Their results showed that MSC transplantation reduced the severity of EAM by inducing neovascularization and inhibiting inflammatory cytokine production. Weener et al. investigated the effect of delivering spleen-derived EPC into a rat model of inflammatory-mediated myocardial damage [125] . They found that EPC caused a functional improvement in cardiac performance evident by higher fractional shortening, reduced scar tissue and thickened ventricular walls. Wang et al. used ESC to attenuate viral myocarditis [126] . They found that a tail vein injection of ESC significantly increased the survival of viral myocarditis mice and decreased the necrosis and infiltration of inflammatory cells. These studies taken together, demonstrate the potential stem cell therapy has in treating myocarditis.

CH is an adaptive response of the heart to pressure overload. However, long term hypertrophy of cardiomyocytes can not maintain normal function and eventually HF will develop. CH is a common feature of the failing myocardium in the progression of some cardiovascular diseases (e.g. hypertension, MI and HF) and is closely related to the pathological changes [127] [128] [129] [130] .

Many investigators have studied the mechanism underlying CH [131] [132] [133] . Recent research has showed that CH is a complicated and dynamic process. It is associated with many genetic and molecular changes related to the regulation of a series of signaling pathways, expression of some cardiac fetal genes, and enhanced of protein synthesis. Interestingly, the increase in cardiac protein synthesis directly causes the enlargement of cardiomyocytes [134, 135] .

Various chemical factors, as well as, mechanical stimulation contribute to the development of the hypertrophic response, which is also the basis of establishing cell and animal models [136] [137] [138] . Many laboratories induce hypertrophic phenotypes on neonatal or adult cardiomyocytes using mediators such as endothelin-1, angiotensin II and leptin [139] [140] [141] [142] . Akimasa Koga and his group constructed an adenovirus vector carrying human wild-type caveolin-3 gene, which was able to prevent phenylephrine and endothelin-1induced hypertrophic responses [143] . While, Galindo and his colleagues compared the transcriptional difference between isoproterenol-induced and exercise-induced CH in mice [144] .

There have been a few reports on stem cell therapy following CH. In general, CH can be suppressed as an accompanying symptom following ischemic injury or HF during treatment. Our team has found that the post-infarct hypertrophic phenotype can be inhibited after erythropoietin treatment, which activated stem cell mobilization and migrate to the infarcted heart [145] .

With the use of small animal disease models in preclinical research, workers have aquirred a large amount of information on the pathogenesis/progression of cardiovascular disease, which has aided the development of effective treatment options. These animal models are effective scientific tools to study the molecular mechanisms of stem cell based therapies for cardiovascular diseases, which potentially provide a powerful approach for discovering new drugs. 

No competing financial interests exist.

Experimental study of bone marrow-derived mesenchymal stem cells combined with hepatocyte growth factor transplantation via noninfarct-relative artery in acute myocardial infarction

Effects of lidocaine and diltiazem on recovery of electrophysiologic activity during partial reperfusion following severe myocardial ischemia in canine hearts

Allogenic mesenchymal stem cell transplantation has a therapeutic effect in acute myocardial infarction in rats

Stem cell therapy with overexpressed VEGF and PDGF genes improves cardiac function in a rat infarct model

Heme oxygenase-1 promotes neovascularization in ischemic heart by coinduction of VEGF and SDF-1

A new animal model of controlled coronary artery occlusion in conscious rabbits

Universal definition of myocardial infarction

Ischemic heart diseases: current treatments and future

Cellular basis of chronic ventricular remodeling after myocardial infarction in rats

Inflammation and postinfarct remodeling: overexpression of IkappaB prevents ventricular dilation via increasing TIMP levels

Enhanced thoracic gene delivery by magnetic nanobead-mediated vector

Intravenous administration of mesenchymal stem cells improves cardiac function in rats with acute myocardial infarction through angiogenesis and myogenesis

Combining angiogenic gene and stem cell therapies for myocardial infarction

Gene delivery to the heart by magnetic nanobeads

Localized and sustained SDF-1 gene release mediated by fibronectin films: A potential method for recruiting stem cells

Localized SDF-1alpha gene release mediated by collagen substrate induces CD117+ stem cell homing

Hypoxic/normoxic preconditioning increases endothelial differentiation potential of human bone marrow CD133+ cells

Small animal models of cardiovascular disease: tools for the study of the roles of metabolic syndrome, dyslipidemia, and atherosclerosis

Experimental myocardial infarction. I. A method of coronary occlusion in small animals

Experimental myocardial infarction in the rat as a quantitative model for the study of antiischemic interventions

Myocardial blood flow, metabolism, and function with repeated brief coronary occlusions in conscious ponies

Myocardial ischemia and reperfusion: a murine model

Bcl-2 engineered MSCs inhibited apoptosis and improved heart function

Mesenchymal stem cell injection after myocardial infarction improves myocardial compliance

Transplantation of embryonic stem cells into the infarcted mouse heart: formation of multiple cell types

Transplantation with survivinengineered mesenchymal stem cells results in better prognosis in a rat model of myocardial infarction

IL-18 binding protein-expressing mesenchymal stem cells improve myocardial protection after ischemia or infarction

Granulocyte colony-stimulating factor exacerbates cardiac fibrosis after myocardial infarction in a rat model of permanent occlusion

Cell therapy attenuates deleterious ventricular remodeling and improves cardiac performance after myocardial infarction

Monolayered mesenchymal stem cells repair scarred myocardium after myocardial infarction

A novel model of cryoinjury-induced myocardial infarction in the mouse: a comparison with coronary artery ligation

Intramyocardial delivery of human CD133+ cells in a SCID mouse cryoinjury model: Bone marrow vs. cord blood-derived cells

Chemical composition and biological activities of essential oil from Salvia sclarea plants regenerated in vitro

Ischaemia induced development of functional coronary collateral circulation in ponies

Entrance in mitosis of adult cardiomyocytes in ischemic pig hearts after plasmid-mediated rhVEGF165 gene transfer

Endothelin A-receptor antagonist administration immediately after experimental myocardial infarction with reperfusion does not affect scar healing in dogs

A novel minimalinvasive model of chronic myocardial infarction in swine

Minimally invasive close-chest method for creating reperfused or occlusive myocardial infarction in swine

Role of free radicals in catecholamine-induced cardiomyopathy

Sequential changes of energy metabolism and mitochondrial function in myocardial infarction induced by isoproterenol in rats: a long-term and integrative study

99mTc-glucarate for detection of isoproterenol-induced myocardial infarction in rats

Adriamycin cardiomyopathy in the rabbit: an animal model of low output cardiac failure with activation of vasoconstrictor mechanisms

Targeted migration of mesenchymal stem cells modified with CXCR4 gene to infarcted myocardium improves cardiac performance

Mesenchymal stem cells and cardiac repair

A transformed cell population derived from cultured mesenchymal stem cells has no functional effect after transplantation into the injured heart

Human cord blood cells induce angiogenesis following myocardial infarction in NOD/scid-mice

Umbilical cord blood cell transplantation for myocardial regeneration

Targeting human CD34+ hematopoietic stem cells with anti-CD45 x anti-myosin light-chain bispecific antibody preserves cardiac function in myocardial infarction

Combined transplantation of skeletal myoblasts and angiopoietic progenitor cells reduces infarct size and apoptosis and improves cardiac function in chronic ischemic heart failure

Endothelial progenitor cells in neovascularization of infarcted myocardium

A new direction for cardiac regeneration therapy: application of synergistically acting epicardium-derived cells and cardiomyocyte progenitor cells

Stem cell-mediated neovascularization in heart repair

Repair of acute myocardial infarction by human stemness factors induced pluripotent stem cells

Stem cell therapy in acute myocardial infarction: a review of clinical trials

Stem cell therapy for cardiac repair: benefits and barriers

Idiopathic dilated cardiomyopathy

Prevalence and etiology of idiopathic dilated cardiomyopathy (summary of a National Heart, Lung, and Blood Institute workshop

Contemporary definitions and classification of the cardiomyopathies: an American Heart Association Scientific Statement from the Council on Clinical Cardiology, Heart Failure and Transplantation Committee; Quality of Care and Outcomes Research and Functional Genomics and Translational Biology Interdisciplinary Working Groups; and Council on Epidemiology and Prevention

Autoimmune mechanisms underlying dilated cardiomyopathy

The therapeutic potential of immune therapy in idiopathic dilated cardiomyopathy

Characterization of antimyocardial autoantibodies in Japanese patients with dilated cardiomyopathy

The frequency of familial dilated cardiomyopathy in a series of patients with idiopathic dilated cardiomyopathy

Familial dilated cardiomyopathy in the United Kingdom

Antigenic analysis of the second extra-cellular loop of the human beta-adrenergic receptors

Epitope analysis of T-and B-cell response against the human beta 1-adrenoceptor

Peptides derived from cardiovascular G-protein-coupled receptors induce morphological cardiomyopathic changes in immunized rabbits

Transfer of rabbit autoimmune cardiomyopathy into severe combined immunodeficiency mice

Induction of cardiomyopathy in severe combined immunodeficiency mice by transfer of lymphocytes from patients with idiopathic dilated cardiomyopathy

Autoantibodies against the second extracellular loop of beta1-adrenergic receptors predict ventricular tachycardia and sudden death in patients with idiopathic dilated cardiomyopathy

A novel class II-binding motif selects peptides that mediate organ-specific autoimmune disease in SWXJ, SJL/J, and SWR/J mice

From myocarditis to cardiomyopathy: mechanisms of inflammation and cell death: learning from the past for the future

Transgenic expression of replication-restricted enteroviral genomes in heart muscle induces defective excitation-contraction coupling and dilated cardiomyopathy

Enteroviral protease 2A cleaves dystrophin: evidence of cytoskeletal disruption in an acquired cardiomyopathy

An experimental model for dilated cardiomyopathy after rabbit coronavirus infection

Dilated cardiomyopathy in retrovirally infected mice: a novel model for silent viral DCM?

Mutation screening in dilated cardiomyopathy: prominent role of the beta myosin heavy chain gene

Actin mutations in dilated cardiomyopathy, a heritable form of heart failure

Cardiac PPARalpha expression in patients with dilated cardiomyopathy

Troponin and cardiomyopathy

Models of dilated cardiomyopathy in the mouse and the hamster

Transcoronary delivery of bone marrow cells to the infarcted murine myocardium: feasibility, cellular kinetics, and improvement in cardiac function

Intracoronary bone marrow cell transfer after myocardial infarction: eighteen months' followup data from the randomized, controlled BOOST (BOne marrOw transfer to enhance ST-elevation infarct regeneration) trial

Transplantation of mesenchymal stem cells improves cardiac function in a rat model of dilated cardiomyopathy

Bone marrow-derived mononuclear cell therapy alleviates left ventricular remodeling and improves heart function in rat-dilated cardiomyopathy

Cardiac matrix remodeling following intracoronary cell transplantation in dilated cardiomyopathic rabbits

Basic fibroblast growth factor improves myocardial function in chronically ischemic porcine hearts

Effects of left circumflex Ameroid constrictor placement on adrenergic innervation of myocardium

An experimental model of chronic myocardial hibernation

Myocardial infarct size and ventricular function in rats

Chronic heart failure induced by coronary artery ligation in Lewis inbred rats

A canine model of chronic heart failure produced by multiple sequential coronary microembolizations

Development and evaluation of a new canine myocardial infarction model using a closedchest injection of thrombogenic material

Myocardial beta adrenoceptor and voltage sensitive calcium channel changes in a canine model of chronic heart failure

SR Ca(2+)-ATPase activity and expression in ventricular myocardium of dogs with heart failure

Ventricular remodeling induced by acute nonocclusive constriction of coronary artery in rats

Coronary constriction impairs cardiac function and induces myocardial damage and ventricular remodeling in mice

Nonischemic myocardial damage induced by nonocclusive constriction of coronary artery in rats

Ameroid constrictor versus hydraulic occluder: creation of hibernating myocardium

Autologous umbilical cord blood mononuclear cell transplantation preserves right ventricular function in a novel model of chronic right ventricular volume overload

Haematopoietic stem cells adopt mature haematopoietic fates in ischaemic myocardium

Haematopoietic stem cells do not transdifferentiate into cardiac myocytes in myocardial infarcts

Implantation of bone marrow mononuclear cells into ischemic myocardium enhances collateral perfusion and regional function via side supply of angioblasts, angiogenic ligands, and cytokines

Determination of bone marrow-derived endothelial progenitor cell significance in angiogenic growth factor-induced neovascularization in vivo

Endothelial cells of hematopoietic origin make a significant contribution to adult blood vessel formation

Diagnosis of myocarditis: death of Dallas criteria

Cardiac myosin induces myocarditis in genetically predisposed mice

Myocarditisinducing epitope of myosin binds constitutively and stably to I-Ak on antigen-presenting cells in the heart

Expression of myosin-class II major histocompatibility complexes in the normal myocardium occurs before induction of autoimmune myocarditis

Autoimmunity in myocarditis: models and mechanisms

A novel experimental model of giant cell myocarditis induced in rats by immunization with cardiac myosin fraction

Depression spectrum disease, I: The role of geneenvironment interaction

Myosin-induced acute myocarditis is a T cellmediated disease

Identification of myocarditogenic peptides derived from cardiac myosin capable of inducing experimental allergic myocarditis in the Lewis rat. The utility of a class II binding motif in selecting self-reactive peptides

Persistent expression of cytokine in the chronic stage of viral myocarditis in mice

Pancreatic expression of interferon-gamma protects mice from lethal coxsackievirus B3 infection and subsequent myocarditis

Myocardial remodeling in viral heart disease: possible interactions between inflammatory mediators and MMP-TIMP system

Inhibition of urokinase-type plasminogen activator or matrix metalloproteinases prevents cardiac injury and dysfunction during viral myocarditis

Left ventricular remodeling in transgenic mice with cardiac restricted overexpression of tumor necrosis factor

Long-term outcome of fulminant myocarditis as compared with acute (nonfulminant) myocarditis

Evidence for mimicry by viral antigens in animal models of autoimmune disease including myocarditis

Dystrophin disruption in enterovirusinduced myocarditis and dilated cardiomyopathy: from bench to bedside

Prominin-1+/CD133+ bone marrow-derived heart-resident cells suppress experimental autoimmune myocarditis

Attenuation of autoimmune myocarditis in rats by mesenchymal stem cell transplantation through enhanced expression of hepatocyte growth factor

Transfer of endothelial progenitor cells improves myocardial performance in rats with dilated cardiomyopathy induced following experimental myocarditis

Embryonic stem cells attenuate viral myocarditis in murine model

Cardiac hypertrophy in hypertension

Cardiac hypertrophy and hypertension

Left ventricular remodeling after myocardial infarction: pathophysiology and therapy

Myocyte death, growth, and regeneration in cardiac hypertrophy and failure

A requirement for the rac1 GTPase in the signal transduction pathway leading to cardiac myocyte hypertrophy

Ventricular remodeling after myocardial infarction. Experimental observations and clinical implications

Statins as antioxidant therapy for preventing cardiac myocyte hypertrophy

Molecular mechanisms underlying the transition of cardiac hypertrophy to heart failure

Cardiac hypertrophy: mechanisms and therapeutic opportunities

Stimulation of hypertrophy of cultured neonatal rat heart cells through an alpha 1-adrenergic receptor and induction of beating through an alpha 1-and beta 1-adrenergic receptor interaction. Evidence for independent regulation of growth and beating

Apoptosis in pressure overload-induced heart hypertrophy in the rat

Rho family small G proteins play critical roles in mechanical stress-induced hypertrophic responses in cardiac myocytes

Contributory role of VEGF overexpression in endothelin-1-induced cardiomyocyte hypertrophy

Inhibition of farnesylpyrophosphate synthase prevents angiotensin II-induced hypertrophic responses in rat neonatal cardiomyocytes: involvement of the RhoA/Rho kinase pathway

Leptin-induced cardiomyocyte hypertrophy involves selective caveolae and RhoA/ROCK-dependent p38 MAPK translocation to nuclei

The obesity-associated peptide leptin induces hypertrophy in neonatal rat ventricular myocytes

Adenovirus-mediated overexpression of caveolin-3 inhibits rat cardiomyocyte hypertrophy

Transcriptional profile of isoproterenol-induced cardiomyopathy and comparison to exercise-induced cardiac hypertrophy and human cardiac failure

Intracardiac injection of erythropoietin induces stem cell recruitment and improves cardiac functions in a rat myocardial infarction model